(lp0
S'Talk Of Bristol-Myers Squibb Co  Acquisition By Pfizer Inc. (NYSE ... Market Exclusive - 19 hours ago According to Credit Suisse, immense value would be created if Pfizer Inc.  were to acquire Bristol-Myers Squibb Co . Analysts at Credit Suisse argue that such an acquisition would positively impact the return on capital of Pfizer ...Bristol-Myers Squibb Company added 0.27% in its Stock Price in the Previous ... - Free ObserverHot Stock Overview: Bristol-Myers Squibb Company  - HugoPress'
p1
aS'Dodge &amp; Cox Buys Bristol-Myers Squibb Company, Zayo Group Holdings, Medtronic ... Nasdaq - Mar 21, 2017 Dodge &amp; Cox initiated holdings in Zayo Group Holdings Inc. Their purchase prices were between $29.81 and $35.14, with an estimated average price of $32.74.'
p2
aS"The Big Reason Bristol-Myers Squibb Company Stock Exploded 15% Higher in February Motley Fool - Mar 7, 2017 Shares of Bristol-Myers Squibb , a U.S. drug giant that's primarily focused on oncology, cardiovascular, and immunoscience therapies, catapulted higher by 15% during February, according to data from S&amp;P Global Market Intelligence.Bristol-Myers Squibb  CEO Giovanni Caforio Presents at Cowen and Company ... - Seeking AlphaInsider Trading Activity Bristol-Myers Squibb Co   EVP Sold 92405 ... - Market Exclusive"
p3
aS'Bristol-Myers Squibb Names New R&amp;D Chief Wall Street Journal  - Mar 8, 2017 Bristol-Myers Squibb Co. said it would replace its research-and-development chief, naming a Massachusetts General Hospital executive to the key job as the company seeks to move past a major drug-development setback.Forget the Distractions: Bristol-Myers Squibb Is a Bargain - Motley FoolBristol-Myers Squibb to Announce Results for First Quarter 2017 on April 27 - Yahoo Finance'
p4
aS"The Technicals For Bristol-Myers Squibb Company  Have Been Dissected ... NY Stock News - 13 hours ago Bristol-Myers Squibb Company  has presented a rich pool of technical data in recent sessions. These are the trends we've been tracking and how we feel they should be played in the current environment."
p5
aS'Bristol-Myers Squibb Company: Parker Institute for Cancer Immunotherapy ... The Wall Street Transcript - 20 hours ago NEW YORK &amp; SAN FRANCISCO----The Parker Institute for Cancer Immunotherapy, Bristol-Myers Squibb Company  and the Cancer Research Institute  today announced a multi-year clinical research collaboration to&nbsp;...Parker Institute, BMS, and CRI Partner on Immuno-Oncology Research - Genetic Engineering & Biotechnology News'
p6
aS'Bristol-Myers Squibb and CytomX Therapeutics Extend Deal Yahoo Finance - Mar 21, 2017 Bristol-Myers Squibb Company BMY and CytomX Therapeutics, Inc. CTMX, announced an expansion of their 2014 strategic collaboration to discover novel therapies.Bristol-Myers Squibb , CtomX Therapeutics  Extend Strategic ... - StreetInsider.comMid-Afternoon Market Update: CytomX Therapeutics Climbs Following Bristol ... - Nasdaq'
p7
aS'Bristol-Myers Squibb to Take Part in Cowen and Company 37th Annual Global ... Yahoo Finance - Feb 27, 2017 Bristol-Myers Squibb Company  will present at the Cowen and Company 37th Annual Global Health Care Conference on Monday, March 6, 2017, in Boston.Owning Bristol-Myers Squibb With Less Risk - Seeking AlphaCarl Icahn Takes Aim at Bristol-Myers Squibb - Motley Fool'
p8
aS"Bristol-Myers Squibb's Valuation Compared to Its Peers' Market Realist - Mar 16, 2017 Headquartered in New York City, Bristol-Myers Squibb  is an American pharmaceutical company dealing in innovative medicines for patients with serious diseases in therapeutic areas such as virology, oncology, cardiovascular, neuroscience, and&nbsp;...Analyst's Predictions on Bristol-Myers Squibb Company , The Kroger Co.  - StockNewsJournalAverage Brokerage Rating Of Bristol-Myers Squibb Company , Oracle ... - The USA Commerce"
p9
aS'Bristol-Myers: A Massive Would-Be Takeover Seeking Alpha - Mar 6, 2017 Carl Icahn is getting more interested in biotech, notably Bristol-Myers Squibb . For starters, Icahn has a stake in BMY, ... The thesis is that the $100 billion drug company might be a buyout target. Generally, the focus is on selling off ...'
p10
a.